Progress in personalizing chemotherapy for bladder cancer.
Progress in personalizing chemotherapy for bladder cancer.
复制标题
DOI：
10.1155/2012/364919
复制
发表时间：
2012
影响因子：
1.4
通讯作者：
Pan CX
中科院分区：
文献类型：
--
作者：
Chang JS;Lara PN Jr;Pan CX
以铂为基础的化疗通常用于治疗局部晚期和转移性膀胱癌。然而，目前还没有方法来预测这种疾病背景下的化疗反应。对膀胱癌生物学的更好理解导致了分子生物标志物的发展，这些分子生物标志物可能有助于指导临床决策。这些生物标记物虽然前景看好，但尚未在前瞻性试验中得到验证，还没有准备好临床应用。作为烷化剂，铂类药物主要通过诱导DNA损伤来杀死癌细胞。目前正在测试一种微剂量方法，以确定是否可以通过使用高灵敏的加速器质谱仪技术测量铂诱导的DNA损伤来确定化疗耐药性。希望这些新出现的策略将有助于为晚期膀胱癌的个性化治疗铺平道路。
Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology of bladder cancer has led to developments of molecular biomarkers that may help guide clinical decision making. These biomarkers, while promising, have not yet been validated in prospective trials and are not ready for clinical applications. As alkylating agents, platinum drugs kill cancer cells mainly through induction of DNA damage. A microdosing approach is currently being tested to determine if chemoresistance can be identified by measuring platinum-induced DNA damage using highly sensitive accelerator mass spectrometry technology. The hope is that these emerging strategies will help pave the road towards personalized therapy in advanced bladder cancer.